| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Precision BioSciences Inc (NASDAQ: DTIL)
DTIL Technical Analysis
5
| As on 9th Jun 2023 DTIL STOCK Price closed @ 0.73 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.68 & Strong Sell for SHORT-TERM with Stoploss of 5.44 we also expect STOCK to react on Following IMPORTANT LEVELS. |
DTILSTOCK Price
| Open | 0.74 | Change | Price | % |
| High | 0.76 | 1 Day | -0.03 | -3.95 |
| Low | 0.73 | 1 Week | -0.01 | -1.35 |
| Close | 0.73 | 1 Month | -0.09 | -10.98 |
| Volume | 505800 | 1 Year | -7.38 | -91.00 |
| 52 Week High 8.47 | 52 Week Low 0.70 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| DTIL Daily Charts |
DTIL Intraday Charts |
Whats New @ Bazaartrend |
DTIL Free Analysis |
|
|
DTIL Important Levels Intraday
| RESISTANCE | 0.79 |
| RESISTANCE | 0.77 |
| RESISTANCE | 0.76 |
| RESISTANCE | 0.75 |
| SUPPORT | 0.71 |
| SUPPORT | 0.70 |
| SUPPORT | 0.69 |
| SUPPORT | 0.67 |
DTIL Forecast May 2024
| 4th UP Forecast | 6.11 |
| 3rd UP Forecast | 4.38 |
| 2nd UP Forecast | 3.32 |
| 1st UP Forecast | 2.25 |
| 1st DOWN Forecast | -0.79 |
| 2nd DOWN Forecast | -1.86 |
| 3rd DOWN Forecast | -2.92 |
| 4th DOWN Forecast | -4.65 |
DTIL Weekly Forecast
| 4th UP Forecast | 3.47 |
| 3rd UP Forecast | 2.59 |
| 2nd UP Forecast | 2.05 |
| 1st UP Forecast | 1.50 |
| 1st DOWN Forecast | -0.04 |
| 2nd DOWN Forecast | -0.59 |
| 3rd DOWN Forecast | -1.13 |
| 4th DOWN Forecast | -2.01 |
DTIL Forecast2024
| 4th UP Forecast | 16.03 |
| 3rd UP Forecast | 11.12 |
| 2nd UP Forecast | 8.09 |
| 1st UP Forecast | 5.06 |
| 1st DOWN Forecast | -3.6 |
| 2nd DOWN Forecast | -6.63 |
| 3rd DOWN Forecast | -9.66 |
| 4th DOWN Forecast | -14.57 |
Precision BioSciences Inc ( NASDAQ USA Symbol : DTIL )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
DTIL Business Profile
Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, which is in Phase 1/2a clinical trial, an allogeneic anti-CD19 CAR T cell product candidate for the patients with relapsed or refractory, or R/R, non-Hodgkin lymphoma, or NHL, or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; and PBCAR20A, that is in Phase 1/2a clinical trial, an allogeneic anti-CD20 CAR T therapy for the treatment NHL, chronic lymphocytic leukemia, and small lymphocytic lymphoma, as well as developing PBCAR269A, which is in Phase 1/2a clinical trial, an allogeneic anti-BCMA CAR T cell product candidate for the treatment of R/R multiple myeloma. The Food segment develops food and nutrition products; and provides technology-centric solutions, Elo life systems, and Elo's technology platform solutions. The company has development and commercial license agreement with Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; and iECURE to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina. Address: 302 East Pettigrew Street, Durham, NC, United States, 27701
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service